Rachel is a Principal based in Versant’s San Francisco office. She is a neurobiologist by training with more than 10 years of experience sourcing new opportunities and leading transactions in business development and portfolio strategy roles across the biotech industry.
Rachel was previously director of business development at Calico Life Sciences, an Alphabet-founded company focused on age-related diseases. At Calico, she established new external partnerships and led the company into a new therapeutic area. Prior to Calico Rachel was Senior Director of Business Development and Portfolio Strategy at Ovid Therapeutics, during which she played a central role in the company’s IPO.
Rachel started her career in non-profit at the Alzheimer’s Drug Discovery Foundation (ADDF) leading early stage preclinical investments and business development activities before working on Wall Street as a sell-side research analyst.
Rachel completed her Ph.D. in cell and molecular biology at the University of Sheffield and postdoctoral research in neurobiology at Icahn School of Medicine at Mount Sinai.